Leucid is progressing novel cart therapies that produce a better and more durable response.
Leucid Bio has raised €14M across 1 funding round from 5 investors, most recently a Series A round in Oct 2021. Based in London, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-10-22 | Series A | €14M |
| 2Invest,Epidarex Capital,Future Fund,Sofinnova Partners,Vulpes Investment Management |
| View deal → |
